Scientific Writer, Integrated Research Management

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 7, 2026

Salary

$143K-$178K From the posting source checked Jun 20, 2026

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$93,011 U.S. median for this role

Projected growth (BLS Employment Projections)

+5.1% - Faster than average

73% above the BLS role benchmark for marketing aggregate.

Matched to SOC 13-1161 - Marketing aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Marketing From the posting source checked Jun 20, 2026

Seniority

Mid From the posting source checked Jun 20, 2026

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Company stage

Late-stage From the posting source checked Jun 20, 2026

Equity

Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Scientific Writer, Integrated Research Management Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a Scientific Writer with strong nonclinical regulatory experience to support the authoring and integration of nonclinical content for U.S. and global regulatory submissions. This role focuses on developing and integrating nonclinical content beyond INDs and NDAs, including briefing documents, Investigator Brochures, responses to health authority questions, and other submission-related materials across the U.S., Europe, and Asia. As a strategic scientific integrator, this individual will translate complex RAS biology and translational pharmacology into clear, compelling regulatory narratives that reflect RevMed's deep mechanistic understanding of RAS signaling and frontier targets. The role partners closely with nonclinical subject matter experts (SMEs) in pharmacology, toxicology, and DMPK, as well as Regulatory Affairs, Regulatory Operations, and Medical Writers, to ensure nonclinical strategy and content are scientifically rigorous, aligned, and submission-ready. The Scientific Writer will leverage structured source documents, document management systems, and emerging AI-enabled

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.